Table 2.

Mt. Sinai Laboratory, Ortho-Clinical VITROS, and Genscript cPASS Assay Results.

Participant	# of SARS-CoV-2 Challenges (Infection(s) and Vaccines) Prior to BT		Days Between Pre-Breakthrough Sample and Last Positive NAAT Test	Icahn SOM at Mt. Sinai Assaya	cPass Assayb	Ortho-Clinical VITROSc
1	3	NI, V2	75	51,200	98, POS	6600
2	2	UI, V2	33	800	<30, NEG	57.4
3	2	UI, V2	16	1600	58, POS	103
4f	3	NII, V1	11	1600	90, POS	116
5d	3	UI, V3	27	51,200	98, POS	6160
6d	3	UI, V3	70	51,200	98, POS	7490
7d, e	4	NI, V3	23	12,800	98, POS	2250
8d, e	4	NI, V3	36	25,600	98, POS	2710
9d	3	UI, V3	86	51,200	98, POS	13,500
10	3	NI, V2	33	6400	<30, NEG	635
11d, e	4	NI, V3	30	25,600	98, POS	4890
12d	3	UI, V3	19	6400	98, POS	1210

UI = No hx of natural infection prior to BT; NI = Hx of natural infection prior to BT; NII: Hx of natural infection 2x prior to BT; V1 = Vaccinated once; V2 = Vaccinated twice; V3 = Vaccinated twice + booster vaccination; BT = Breakthrough infection.

^aDiscrete antibody titers may be reported from 1:100 to 204,800, though in this study discrete titers were only observed up to 51,200.

^bSurrogate neutralizing activity was reported from <30% to 100% (<30% = Neg, 30–100% = Pos).

^cUndiluted linear range 2–200 BAU/ml, samples diluted as needed to achieve result in linear range of 2–200 BAU/ml.

^dReceived a booster vaccination.

^eReceived a Moderna mRNA-1273 half dose.

^fReceived Johnson & Johnson Ad26.COV2.S as primary vaccination.